Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.